Entries by Inmunotek

INMUNOTEK Top-10 according to Pharma Tech Outlook

INMUNOTEK Top-10 according to Pharma Tech Outlook {$excerpt:n} 10/2020. INMUNOTEK featured by Pharma Tech Outlook INMUNOTEK is the cover of  Pharma Tech Outlook, a magazine specialized in pharmaceutical technology, after being recognized among the main European providers of immunotherapies.  According to the magazine, immunotherapy, which is applied to autoimmune and infectious diseases, cancer or […]

INMUNOTEK at the A TU SALUD awards

INMUNOTEK at the A TU SALUD awards {$excerpt:n} 09/2020. INMUNOTEK at A TU SALUD awards INMUNOTEK has been awarded in the ninth edition of the A TU SALUD awards with the mention Immunology, a discipline recognized this year for the first time for its relevance in the current pandemic situation. The Spanish newspaper LA […]

MV140 (Uromune) in recurrent urinary tract infections

MV140 (Uromune) in recurrent urinary tract infections {$excerpt:n} . 08/2020. Uromune-MV140. A systematic Review A systematic review on MV140 (Uromune) has been published. All relevant clinical studies published have been considered to globally assess the impact of this vaccine in the treatment of recurrent urinary tract infections.    MV140 (Uromune) is a sublingual bacterial […]

INMUNOTEK receives the National Innovation Award

INMUNOTEK receives the National Innovation Award {$excerpt:n} 07/2020. Awards Presentation Ceremony INMUNOTEK receives the National Innovation Award from their Majesties the Kings of Spain with the assistance of the Minister of Science and Innovation. The National Innovation Award is the highest award from the Government of Spain for recognizing the entities that make innovation […]

INMUNOTEK innovative entity granted by BLOCKPCT

INMUNOTEK innovative entity granted by BLOCKPCT {$excerpt:n} 06/2020. Innovative Entity Certification INMUNOTEK has received the innovative entity certification issued by BLOCKPCT   Madrid Activa SAU, managing entity of the TECNOALCALÁ Science and Technology Park, has registered INMUNOTEK as innovative entity in the blockchain network of Spanish Science and Technology parks (BLOCKPCT), promoted by the Association […]

Supply of Products and COVID-19

Supply of Products and COVID-19 {$excerpt:n} 03/2019. Information regarding COVID-19 INMUNOTEK information note on the supply of its products.   In these extraordinarily difficult times, we want to assure our prescribers and patients that despite the situation of confinement established in Spain, our company continues to work to fulfill its commitments. We have adapted […]

COVID-19: INMUNOTEK invited by ITTN

COVID-19: INMUNOTEK invited by ITTN {$excerpt:n} 03/2020. ITTN selects MV130 project The project presented by INMUNOTEK has been selected in the “International Innovative Technology against COVID-19” an event organized by ITTN (International Technology Transfer Network) under the auspices of CAST (China Association for Science and Technology).   INMUNOTEK has presented its project MV130 based […]

INMUNOTEK´s research in Allergy Virtual Issue

INMUNOTEK´s research in Allergy Virtual Issue {$excerpt:n} 03/2020. Virtual Issue includes INMUNOTEK´s research Virtual Issue is a collection of recently published articles in Allergy selected by the Editor-in-Chief on a topic of high interest that are made available Free Access by the journal. Its aim is to bring these articles to the attention of […]

Financial Times features INMUNOTEK

Financial Times features INMUNOTEK {$excerpt:n} 12/2019. INMUNOTEK en Financial Times The Financial Times features INMUNOTEK as a successful company capable of overcoming economic and political turbulences in a special report on business and innovation in Spain.   According to the Financial Times (FT), innovation and competitiveness shield Spanish companies from eventual turbulences associated with […]

MyTomorrows and INMUNOTEK collaboration

MyTomorrows and INMUNOTEK collaboration {$excerpt:n} 12/2019. Expanded Access Program Joint press release from myTomorrows and Inmunotek myTomorrows and Inmunotek to develop Expanded Access Program Amsterdam, The Netherlands and Madrid, Spain, 12 December, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Inmunotek – with headquarters […]